tagraxofusp

IV (Adults and Children ≥2 yr): 12 mcg/kg once daily on Days 1–5 of every 21-day cycle. Continue until disease progression or unacceptable toxicity.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Fusion protein composed of a recombinant human interleukin-3 and truncated diphtheria toxin that inhibits protein synthesis and causes cell death in cells that express CD123.

Therapeutic effects:

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: cytotoxic proteins

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: 42 min.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
IV	unknown	unknown	unknown

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication to patient. Advise to read Patient Information before starting therapy.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other medications.
Advise patient of the risk of capillary leak syndrome and to notify health care professional if new or worsening edema, weight gain, shortness of breath, or low BP occur after infusion. Advise patient to weigh themselves daily.
Advise patient to notify health care professional if rash, flushing, wheezing, or swelling of the face occurs. Seek immediate medical attention if needed.
Inform patient to report any symptoms of elevated liver enzymes, including tiredness, anorexia, or right upper abdominal discomfort.
Advise patient to avoid large crowds and people who are sick and to report flu-like symptoms and fever.
Advise patient to report any signs of bleeding including bruising easily, bleeding gums, or nosebleeds.
Rep: May cause fetal harm. Advise women of reproductive potential to notify health care professional if pregnancy is suspected or planned. Advise patient to use acceptable contraceptive methods and to avoid breastfeeding during treatment and for 1 wk after last dose.